Business Wire

The First of Five Architectural Masterpieces at The Case, Malibu’s Only New Guard Gate Community in Decades, Lists for $69.995 Million

16.6.2022 00:51:00 EEST | Business Wire | Press release

Share

After more than a decade in approvals, design, and construction, Scott Gillen, visionary home designer, creator and founder of Unvarnished, has listed for sale the first of five estates in the 24-acre private enclave known as The Case. The first guard gated community built in Malibu in decades, The Case comprises five spectacular mid-century modern inspired homes perched above The Colony on Malibu’s most coveted oceanfront bluff and represents the largest private residential development in its history. The Edge, on the market for $69.995 million, will be the first home completed within the community and will be delivered turnkey, providing the buyer instant gratification of unprecedented luxury and hand-crafted design perfection. All five bespoke homes are currently under construction, with the remaining homes slated for full completion throughout the year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615006048/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Edge (Photo: Business Wire)

“The Case is my largest and most epic project to date. The opportunity to create a community of five homes on one of, if not the best bluff top on the California coast, was something I could not pass up. Frankly, ten minutes after I stepped on the property, I knew I would buy it,” said Scott Gillen, the founder of Unvarnished. “The sheer size of the property and the ability to build 10,000 to 12,000-square foot single story homes created immense challenges and unbelievable opportunities for me to take some of my foundational design principles--use of warm natural materials, a nod toward mid-century modern, large, opened spaces, lots of natural light and blurring the line between indoors and out-- which are also tenets of mid-century modern architecture--to the next level. So, it was natural that my designs for The Edge, and the other homes at The Case, take enormous inspiration from mid-century modern architecture, and then I incorporate construction techniques and furnishings, the quality of which are rarely, if ever, found in new development, to create a unique experience of luxury living on the coast of Malibu, a place unlike anywhere else in the world. I’m very proud of how The Edge has turned out and I’m incredibly excited to bring it to market.”

The 2.6-acre estate, providing cinematic views of the Queen’s necklace, Palos Verdes to Point Dume, embodies the essence of casual luxury living. Spanning approximately 10,500 square feet, the single-story home offers five ensuite bedrooms and three half baths, and includes a Bulthaup chef’s kitchen, expansive great room, a master bedroom with outdoor spa, and floor to ceiling glass doors that open to a 10,000-square foot Ipe deck with cabana and outdoor kitchen.

The Edge, named for its stunning nearly 80-foot double-sided infinity edge freshwater pool that juts out like a diving board into the Pacific Ocean, with famed Catalina Island in the distance, is architecturally inspired by the giants of mid-century modern, Lloyd Wright, Neutra, Lautner and Quincy Jones, to name but a few. The magnificent home also includes hand-picked custom furnishings by Minotti and Gillen, Miele and Gaggenau appliances, custom cabinets, a 650-bottle teak wine room, a glass and teak enclosed private library, and a home theatre that is a room “floating” inside another room to achieve the ultimate home cinema experience.

The Case is the crown jewel of Scott Gillen’s visionary Malibu Series, where each home is a sanctuary unto itself. Behind its 24-hour manned guard gate and security features designed by international renowned security expert Gavin de Becker, residents of The Case will live with ultimate peace of mind and privacy.

The Case comprises five distinct mid-century modern homes: The Cantilever House (Case Study No. 1), The Butterfly House (Case Study No. 2), The Edge (Case Study No. 3), The Flat House (Case Study No. 4) and The Glass Tunnel (Case Study No. 5).

For more information, visit www.unvarnishedco.com or contact listing agent Sandro Dazzan of The Agency.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Emily Warner
Murphy O’Brien Public Relations
unvarnishedcopr@murphyobrien.com 
310.453.2539

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive

emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release

emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead

Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release

Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme

EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release

European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release

ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye